Loading...
OTCMIUGNF
Market cap166mUSD
Dec 30, Last price  
0.03USD
1D
6.00%
1Q
-25.51%
Name

Imugene Ltd

Chart & Performance

D1W1MN
OTCM:IUGNF chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.63%
Rev. gr., 5y
26.55%
Revenues
0k
-100.00%
00374,5640002,227,028235,912207,220538,312638,6761,564,2711,164,0491,840,7864,127,2814,133,8417,231,54512,969,88311,777,6280
Net income
-150m
L+294.78%
-1,794,208-2,187,219-2,304,263-1,910,925650,286-1,535,041415,539-3,133,433-1,559,566-2,115,964-2,440,789-2,730,642-2,506,571-3,933,641-7,775,360-10,507,999-18,455,363-37,869,174-37,914,890-149,680,539
CFO
-97m
L+226.82%
-1,629,008-1,833,137-1,702,853-1,272,900881,768-1,742,8101,090,407-965,922-1,368,643-1,144,098-2,043,584-3,049,543-2,673,024-4,508,037-7,909,490-10,132,111-13,129,120-30,668,544-29,778,710-97,322,640
Earnings
Feb 27, 2025

Profile

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
URL
https://www.imugene.com/
IPO date
Dec 02, 1993
Employees
0
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
11,778
-9.19%
12,970
79.35%
Cost of revenue
92,725
54,004
53,415
Unusual Expense (Income)
NOPBT
(92,725)
(42,226)
(40,445)
NOPBT Margin
Operating Taxes
(4,615)
(11,742)
(12,614)
Tax Rate
NOPAT
(88,110)
(30,484)
(27,831)
Net income
(149,681)
294.78%
(37,915)
0.12%
(37,869)
105.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
50,968
78,086
96,574
BB yield
-12.61%
-13.67%
-9.52%
Debt
Debt current
912
191
184
Long-term debt
634
725
979
Deferred revenue
Other long-term liabilities
3,845
991
987
Net debt
(95,409)
(152,452)
(98,977)
Cash flow
Cash from operating activities
(97,323)
(29,779)
(30,669)
CAPEX
(9,455)
(258)
Cash from investing activities
(11,654)
10
(414)
Cash from financing activities
49,428
82,981
101,354
FCF
(82,512)
(30,281)
(32,385)
Balance
Cash
94,543
153,151
99,888
Long term investments
2,413
218
252
Excess cash
96,956
152,779
99,492
Stockholders' equity
118,254
189,626
138,705
Invested Capital
26,056
38,391
40,874
ROIC
ROCE
EV
Common stock shares outstanding
7,088,808
6,275,676
5,637,197
Price
0.06
-37.36%
0.09
-49.44%
0.18
-49.30%
Market cap
404,062
-29.25%
571,086
-43.72%
1,014,695
-38.71%
EV
308,653
418,634
915,718
EBITDA
(92,725)
(40,022)
(38,038)
EV/EBITDA
Interest
478
27
14
Interest/NOPBT